Lexicon Pharmaceuticals CEO Michael Exton reports acquisition of $49,999.4384 in common shares
LXRX•CEO and director Michael Exton purchased 30,064 Lexicon Pharmaceuticals common shares at $1.6631 each, increasing his direct holdings to 328,496 shares.
1. Share purchase
Michael Exton purchased 30,064 shares of Lexicon Pharmaceuticals common stock at $1.6631 per share, bringing his direct holdings to 328,496 shares.
